跳至主要内容
临床试验/NCT01557608
NCT01557608已完成不适用

Characterization of and Treatment for Chemotherapy-Induced Neuropathy

University of California, San Francisco2 个研究点 分布在 1 个国家目标入组 754 人开始时间: 2012年4月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
754
试验地点
2
主要终点
Changes over time in light touch sensation

研究概览

简要总结

Numbness, tingling, and pain in the hands and feet following the administration of chemotherapy (also called chemotherapy-induced neuropathy (CIN)) is a common problem in oncology patients. However, more information is needed on why patients develop neuropathy and how it impacts their mood, ability to function, and their quality of life. In addition, effective treatments for this problem are not available at the present time. This study will be conducted in two parts. In Part 1, patients who have finished chemotherapy and did or did not develop CIN will be evaluated to determine why some patients do and other patients do not develop CIN. In addition, the impact of CIN on patients' mood, function, and quality of life will be evaluated by comparing patients' reports on these important outcome measures. In addition, genetic markers that contribute to or protect against the development of CIN will be evaluated. Part 2 of this study will test the effects of a new treatment called photon stimulation (also called infrared light therapy) compared to placebo treatment to improve sensations in the feet of oncology patients with CIN. Patients who receive the photon stimulation will have greater improvement in sensation in their feet compared with those who do not receive photon stimulation.

详细描述

This protocol is designed in two parts. Part 1 will use an "extreme phenotype" approach to evaluate the phenotypic and genotypic characteristics of chemotherapy induced neuropathy(CIN)in a sample of oncology patients who have completed their chemotherapy and did(n=400)and did not (n=200) develop CIN. Patients with and without CIN will be matched, in a 2 to 1 ratio, on their cancer diagnosis and CTX agents administered (i.e., only a platinum compound, only a taxane, or both). Patients will be recruited in cohorts of 30 to 40 to insure that the matching criteria are met and the 2:1 ratio is achieved.

In a single study visit, to take place at the outpatient CTSI CRC (CCRC) at Mt. Zion,participants will be enrolled, complete a battery of sensorimotor tests and questionnaires, and provide a single blood specimen for genomic analysis.

Part 2 will be a pilot study of a randomized, double-blind, placebo-controlled clinical trial (RDBPCT) of photon stimulation in a sample of patients (n=142) with CIN who participated in Part 1. Participants will be randomized to receive the active treatment or the placebo in a series of 8 treatments, lasting 7 minutes each, across a 14-day period. Participants will be assessed at baseline and after the 2nd, 4th, 6th, and 8th treatments with sensory, motor, balance, pain intensity and pain quality measures, mood, and quality of life measures. Blood specimens will be drawn on treatment days 1, 4, 5, and 8 for gene expression.

10.1 * Study design: 10.2 Check

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • is an adult >18 years of age;
  • has received a platinum compound and/or a taxane;
  • has completed a course of CTX;
  • has changes in sensation and/or pain in their feet of >3 months duration following the completion of CTX;
  • has a rating of >3 on a 0 to 10 numeric rating scale (NRS) on any one of the following sensations from the Pain Qualities Assessment Scale (i.e., numb, tender, shooting, sensitive, electrical, tingling radiating, throbbing, cramping, itchy, unpleasant),91
  • if they have pain associated with the CIN, has an average pain intensity score in their feet of >3 on a 0 to 10 NRS;
  • has a Karnofsky Performance Status (KPS) score of >50;
  • is able to read, write, and understand English; and
  • signs a written informed consent.

排除标准

  • If they have CIN in their hands, because we have no experience treating CIN in patients' hands with photon stimulation and the photon stimulator is designed to provide treatment only to the feet.
  • Women will be excluded if they intend to become or are pregnant or lactating. Men and women will be required to take active measures to prevent pregnancy while on the study.
  • If unwilling to provide the scheduled blood specimens they will be excluded.

结局指标

主要结局

Changes over time in light touch sensation

时间窗: Treatment days 1, 2, 4, 6, and 8

Light touch sensation will be measured using Semmes Weinstein monofilaments.

次要结局

  • Safety measures(Before and after each treatment on days 1 through 8)
  • Changes over time in average pain intensity(Treatment days 1 through 8)
  • Changes over time in pain qualities(Treatment days 2, 4, 6, 8)
  • Changes over time in worst pain intensity(Treatment days 1 through 8)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验